Posted by Michael Wonder on 15 Jan 2021
China National Medical Products Administration approves tislelizumab in combination with chemotherapy in first-line advanced squamous non-small cell lung cancer
13 January 2021 - BeiGene today announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration for use in combination with two chemotherapy regimens as a first-line treatment for patients with advanced squamous non-small cell lung cancer.
This is the third approval in China for tislelizumab, and its first in a lung cancer indication.
